Valneva SE
Research Valneva SE (VALN) on Bullrun: market cap USD 444.85M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerVALN
- ExchangeNASDAQ
- CountryFrance
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 444.85M
- Financial periodQ1 2026
- RevenueUSD 30.90M
- Net income-USD 32.07M
- Free cash flow-USD 565.00K
- Gross margin15.3%
Valuation Snapshot
latest market cap is USD 444.85M.
About Valneva SE
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium;
Frequently asked questions
What is Valneva SE's market cap?
Valneva SE's market capitalization is USD 444.85M.
What does Valneva SE do?
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis;